Document

                                                                                                                           Exhibit 10.1

AMENDMENT NO. 3 TO
PATENT AND TECHNOLOGY LICENSE AGREEMENT


This Amendment No. 3, effective this 20th day of May, 2020 (“Amendment No. 3 Effective Date”), to that certain Patent and Technology License Agreement between the Parties dated April 2, 2012, as previously amended by Amendment No.1 dated October 19, 2015 and Amendment No. 2 dated November 1, 2018 (as so amended, the “Original License”), is made by and between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, on behalf of The University of Texas M. D. Anderson Cancer Center (hereinafter “UTMDACC”), a member institution of System, and Moleculin Biotech, Inc. (hereinafter “Licensee”), a Delaware corporation having a principal place of business located at 5300 Memorial Dr., Suite 950, Houston, Texas 77007. Board, on behalf of UTMDACC, and Licensee may herein be referred to collectively as the “Parties.”


RECITALS


A.Moleculin Biotech, Inc. is the assignee of the Original License pursuant to that certain Assignment and Assumption Agreement dated November 17, 2015. Accordingly, Moleculin Biotech, Inc. may be referenced herein as the “Licensee.”


B.Board and Licensee desire to amend the Original License.


NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the Parties hereby agree to the following:


AMENDED TERMS


1.As consideration for this Amendment No. 3, Licensee shall pay UTMDACC, without invoice, the amount of $[***] not later than ten (10) days after the Amendment No. 3 Effective Date.


2.Subsections (b) and (c) of Section 13.2 of the Original License shall be deleted in their entirety and replaced with the following:


(b)within nine (9) months after the Amendment No. 3 Effective Date, file an INVESTIGATIONAL NEW DRUG APPLICATION with the FDA for a PHASE I STUDY for a LICENSED PRODUCT;


(c)within two and one-half (2.5) years after the Amendment No. 3 Effective Date, commence a PHASE I STUDY for a LICENSED PRODUCT; and














CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***]








                                                                                                                           Exhibit 10.1

(d)within four and one-half (4.5) years after the Amendment No. 3 Effective Date, commence a PHASE II STUDY for a LICENSED PRODUCT.


As used in Subsections 13.2(c) and 13.2(d) above, a PHASE I STUDY, or a PHASE II STUDY, shall be deemed to commence upon the administration of a LICENSED PRODUCT or placebo to the first patient enrolled in the PHASE I STUDY, or PHASE II STUDY, respectively.


Licensee may extend any of the deadlines for achieving the milestones set forth in Subsections (b) – (d) above, up to a maximum of three (3) times, upon written notice to UTMDACC requesting an extension and full payment of the Extension Fee, as defined below, prior to expiration of the respective deadline. For purposes of this Agreement, the term “Extension Fee” shall mean the amount set forth in Table 13.2 below for each deadline extension request. Upon payment of each Extension Fee with respect to any of such milestones, an additional six months will be added to the time for completion of such milestone and all other as yet unmet milestones in Subsections (b) – (d) above. It is understood and agreed that time is of the essence with respect to payment of the Extension Fee, and failure to timely pay an Extension Fee shall not be subject to any cure period. In no event shall any of the deadlines in Subsections (b) – (d) above be subject to more than three (3) six month extensions.
 
						
	Table 13.2	
	Extension	Extension Fee
	First six (6) month extension	$[***]
	Second six (6) month extension	$[***]
	Third six (6) month extension	$[***]




3.Licensee shall be solely responsible for timely submission of this Amendment No. 3, or any portions thereof, to any securities exchange or any governmental or quasi- governmental entity if required by applicable law or regulation.


4.This Amendment No. 3 shall be construed and enforced in accordance with the laws of the United States of America and the State of Texas, without regard to its conflict of law provisions.


5.The Parties acknowledge and agree that, except as set forth in this Amendment No. 3, the terms and conditions of the Original License shall remain in full force and effect. Moreover, this Amendment No. 3 shall not modify or supersede any other agreements between the Parties.












CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***]








                                                                                                                           Exhibit 10.1



IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Amendment No. 3.









BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, on
behalf of
THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER


By                         [***]
     Printed Name:       [***]
     Title:                      [***]
     Date:                      May 20, 2020






     MOLECULIN BIOTECH, INC.


     By                         /s/ Walter V. Klemp
     Printed Name:       Walter V. Klemp
     Title:                      Chairman & CEO
     Date:                       May 20, 2020






Approved as to Content:


By [***]
      [***], J.D., Ph.D.
Senior Vice President
Res. Administration & Industry Relations Strategic Industry Ventures
M. D. Anderson Cancer Center




Date: May 20, 2020






























CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***]